Patent 12064485 was granted and assigned to Amicus Therapeutics on August, 2024 by the United States Patent and Trademark Office.
Provided herein are polypeptides comprising one or more non-native cysteine residues that form a disulfide bridge between non-native cysteines within the protein or between non-native cysteines of two monomers of the protein. Such modified human polypeptides are useful in treatment of genetic diseases via enzyme replacement therapy and/or gene therapy.